# Metformin Regulation of the Liver Circadian Clock and Metabolic Aging: A Systems Modeling Study

**Authors:** Mengyuan Zhang, Ying Li

PMC · DOI: 10.3390/metabo16030208 · 2026-03-20

## TL;DR

This study shows that metformin's effects on liver circadian rhythms and aging depend on the time of administration and the feeding state, suggesting optimal treatment strategies.

## Contribution

The study introduces a systems modeling approach to optimize metformin administration for anti-aging effects based on circadian timing and metabolic state.

## Key findings

- Metformin's effects on the liver circadian clock and aging markers are phase-dependent.
- Fasting enhances metformin's anti-aging effects, while a high-fat diet reduces them.
- Administering metformin during the increasing phase of CLOCK-BMAL1 concentration yields positive outcomes.

## Abstract

What are the main findings?
•Metformin exerts phase-dependent effects on liver circadian dynamics and metabolic aging markers.•Feeding state critically modulates metformin responses, with fasting enhancing and high-fat diet attenuating anti-aging effects.

Metformin exerts phase-dependent effects on liver circadian dynamics and metabolic aging markers.

Feeding state critically modulates metformin responses, with fasting enhancing and high-fat diet attenuating anti-aging effects.

What is the implication of the main finding?
•Optimizing metformin treatment according to circadian time and metabolic state may enhance anti-aging efficacy and support more flexible drug intervention strategies.

Optimizing metformin treatment according to circadian time and metabolic state may enhance anti-aging efficacy and support more flexible drug intervention strategies.

Introduction: Aging affects both metabolic and circadian systems, leading to disruptions in energy homeostasis and phase shifts in the circadian clock. Metformin, a widely used antihyperglycemic drug, exerts anti-aging effects by modulating key pathways in the liver and also influences the liver circadian clock. However, the optimal medication strategy, including dosage and timing, that achieves significant anti-aging effects while minimizing negative impacts on the circadian clock remains unclear. This study aims to identify a rational metformin administration strategy considering both aspects. Methods: An extended mathematical model of the liver circadian clock incorporating metformin regulation was developed, and numerical simulations were performed to evaluate different dosing times and feeding conditions. Results: Metformin administration at different times produced distinct effects on both the circadian clock and anti-aging outcomes. Administration during the increasing phase of CLOCK-BMAL1 concentration showed positive effects on the circadian clock and effective anti-aging properties. Regarding feeding patterns, a fed-like state was not conducive to anti-aging, whereas fasting was beneficial. Conclusions: These findings highlight the importance of dosing time and feeding styles in optimizing metformin efficacy and provide insights into its potential pharmacological applications in anti-aging therapy.

## Linked entities

- **Genes:** CLOCK (clock circadian regulator) [NCBI Gene 9575], BMAL1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 406]
- **Chemicals:** metformin (PubChem CID 4091)

## Full-text entities

- **Genes:** LINC-ROR (long intergenic non-protein coding RNA, regulator of reprogramming) [NCBI Gene 100885779] {aka ROR, lincRNA-RoR, lincRNA-ST8SIA3}, Clock (clock circadian regulator) [NCBI Gene 12753] {aka 5330400M04Rik, KAT13D}, PSENEN (presenilin enhancer, gamma-secretase subunit) [NCBI Gene 55851] {aka ACNINV2, MDS033, MSTP064, PEN-2, PEN2}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PER2 (period circadian regulator 2) [NCBI Gene 8864] {aka FASPS, FASPS1}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MAGEA8 (MAGE family member A8) [NCBI Gene 4107] {aka CT1.8, MAGE8}, CLOCK (clock circadian regulator) [NCBI Gene 9575] {aka KAT13D, bHLHe8}, BMAL1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 406] {aka ARNTL, ARNTL1, BMAL1c, JAP3, MOP3, PASD3}, ATP6AP1 (ATPase H+ transporting accessory protein 1) [NCBI Gene 537] {aka 16A, ATP6IP1, ATP6S1, Ac45, CF2, VATPS1}, Sirt1 (sirtuin 1) [NCBI Gene 93759] {aka SIR2L1, Sir2, Sir2a, Sir2alpha}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, Bmal1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 11865] {aka Arnt3, Arntl, BMAL1b, MOP3, bHLHe5, bmal1b'}
- **Diseases:** depression (MESH:D003866), T2D (MESH:D003924), schizophrenia (MESH:D012559), injury to (MESH:D014947), insulin resistance (MESH:D007333), mitochondrial functional decline (MESH:D028361), diabetes (MESH:D003920), cognitive decline (MESH:D003072), cancer (MESH:D009369), metabolic diseases (MESH:D008659), dementia (MESH:D003704), metabolic syndrome (MESH:D024821)
- **Chemicals:** rapamycin (MESH:D020123), AMP (MESH:D000249), wortmannin (MESH:D000077191), CT8 (-), fat (MESH:D005223), resveratrol (MESH:D000077185), NAD+ (MESH:D009243), glucose (MESH:D005947), melatonin (MESH:D008550), Metformin (MESH:D008687)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027763/full.md

---
Source: https://tomesphere.com/paper/PMC13027763